Locoregional Control After Breast Conserving Treatment in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer

In the last decade Neoadjuvant Chemotherapy (NAC) has become more common for patients with operable breast cancer.Greatest advantage of this approach is that it can increase the proportion of patients who can be treated with Breast Conserving Therapy (BCT).This is a retrospective study of a prospective database regarding 573 patients, consecutively treated with BCT and ALND, among these 84 were treated with NAC.Primary end-point of this study was to evaluate long-term outcomes of patients treated with BCT after NAC.Secondarily we evaluated same outcomes in populations with comparable initial clinical stage; more over factors affecting the risk of developing a Locoregional Recurernce (LRR) were investigated.Incidence rate registered for LRR was 1/100 person per year for patients treated with adjuvant chemotherapy, while it is doubled in the NAC-group with 2/100 person per year.Ipsilateral breast tumour recurrences' incidence rate was 1 IBTR per 100 persons per year in the first group and twice as much in the NAC-group.When considering only patients initially staged cT2, there is no significant difference in terms of outcome at 5 and 10 years.NAC shows equivalent outcomes compared to BCT and adjuvant chemotherapy especially when our case-series is analyzed by presenting clinical tumor stage, leading to satisfactory locoregional outcomes without affecting overall survival of patients, thus increasing considerably the rates of patients eligible for conservative treatment.